BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
2.380 USD    0.00%
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Biotech : Announces Results of 2021 Annual General Meeting - Form 6-K

12/29/2021 | 06:17am EDT

Burning Rock Announces Results of 2021 Annual General Meeting

GUANGZHOU, China, December 28, 2021-Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2021 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions approving:

1.

the ratification of the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 and the authorization for the directors of the Company to determine the remuneration of the auditor;

2.

the re-election of Yusheng Han, Gang Lu and Shaokun Chuai as directors of the Company;

3.

the approval, confirmation and ratification of the adoption of the 2021 Long-term Equity Incentive Plan and the grant of options thereunder, the vesting of which is tied to the Company's future stock performances; and

4.

the authorization of each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

Disclaimer

Burning Rock Biotech Ltd. published this content on 29 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 December 2021 11:16:01 UTC.


© Publicnow 2021
All news about BURNING ROCK BIOTECH LIMITED
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form ..
PU
03/22Burning Rock Biotech Limited Reports Earnings Results for the Full Year Ended December ..
CI
03/22TRANSCRIPT : Burning Rock Biotech Limited, Q4 2021 Earnings Call, Mar 22, 2022
CI
03/22Burning Rock Biotech's Q4 Loss Widens, Revenue Rises
MT
03/21BURNING ROCK BIOTECH : Q4 2021 Presentation Slides
PU
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Biotech Limited Provides Revenue Guidance for the Year 2022
CI
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2022 620 M 92,5 M 92,5 M
Net income 2022 -656 M -97,9 M -97,9 M
Net cash 2022 673 M 100 M 100 M
P/E ratio 2022 -2,56x
Yield 2022 -
Capitalization 1 677 M 250 M 250 M
EV / Sales 2022 1,62x
EV / Sales 2023 0,49x
Nbr of Employees 1 394
Free-Float 67,9%
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 15,94 CNY
Average target price 84,82 CNY
Spread / Average Target 432%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Technology Officer
Wendy Hayes Independent Director
Sector and Competitors